Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion, with adjusted earnings per diluted share at $33.5, exceeding expectations and reflecting a year-over-year EPS growth of 20% [5][40][42] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth across the business [32][29] - Operating profit for the full year increased 15% to $5.6 billion, with significant contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments [41][42] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment saw revenues increase by 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty product distribution [33][22] - The Prescription Technology Solutions segment reported a revenue increase of 13% to $1.3 billion, with operating profit rising 34% to $285 million, reflecting increased prescription transaction volumes [34][35] - The Medical Surgical Solutions segment experienced a 1% revenue increase to $2.9 billion, with operating profit up 15% to $285 million, benefiting from cost optimization initiatives [37][36] Market Data and Key Metrics Changes - The Canadian business, part of the international segment, reported revenues of $3.5 billion, a decrease of 2% due to the divestiture of certain businesses, but operating profit increased by 9% [38][24] - The company anticipates continued growth in the Canadian distribution business, partially offset by the impact of previous divestitures [58] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of a controlling interest in Prism Vision and Core Ventures, aimed at enhancing community-based care [6][12][49] - A strategic decision was made to separate the Medical Surgical segment into an independent company to enhance operational focus and capital deployment [19][27] - The company plans to continue investing in technology, automation, and AI to improve operational efficiencies and customer service [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to maintain momentum and deliver strong results in fiscal 2026, with anticipated revenue growth of 11% to 15% and operating profit growth of 8% to 12% [43][44] - The company remains committed to maximizing shareholder value through disciplined portfolio management and strategic capital deployment [27][62] Other Important Information - The company returned $3.5 billion to shareholders in fiscal 2025, including $3.1 billion through share repurchases [42] - Free cash flow for the fourth quarter was robust at $7.5 billion, driven by strong operating results [39] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no concrete announcements regarding Medicare Part B impacts, and any potential changes would likely face legal challenges [65][66] Question: Tariff Impacts on Business - Management is closely monitoring the tariff landscape and believes that current assessments have been incorporated into guidance, with no material impact anticipated on fiscal 2026 results [75][81] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [85][88] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in long-term guidance reflects a stable environment for prescription utilization and successful capital deployment in oncology and other specialties [92][96]

McKesson Corporation Fiscal 2025 Financial Results Fiscal 2026 Outlook May 8, 2025 Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "projects," "plans," "estimat ...

Exhibit 99.1 McKESSON REPORTS FISCAL 2025 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES FISCAL 2026 GUIDANCE; ANNOUNCES INTENT TO SEPARATE MEDICAL-SURGICAL SOLUTIONS IRVING, Texas, May 8, 2025 - McKesson Corporation (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2025. Fourth Quarter Highlights: Full Year Highlights: "McKesson delivered strong fourth quarter performance reporting revenue growth of 19% and Adjusted Earnings per Diluted Share growth of 64%. This m ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about McKesson (MCK) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.McKesson currently has an average brokerage ...

Core Viewpoint - McKesson Corporation is expected to report significant revenue and earnings growth in the fourth quarter of fiscal 2025, driven by the adoption of GLP-1 weight loss drugs, demand for specialty pharmaceuticals, and investments in technology and distribution [1][3][16]. Revenue Growth Drivers - The rapid adoption of GLP-1 weight loss drugs and sustained demand for branded pharmaceuticals have significantly fueled McKesson's revenue growth [1][6]. - A rebound in primary care visits has also supported top-line growth in the last two reported quarters [2]. - Investments in expanding distribution centers and integrating artificial intelligence into services have bolstered revenues [2][20]. Earnings Estimates - The Zacks Consensus Estimate for earnings is $9.81 per share, reflecting a 58.7% year-over-year improvement [3]. - The consensus revenue estimate is $93.7 billion, indicating a 22.7% year-over-year surge [3]. Segment Performance Insights - The U.S. Pharmaceutical segment is expected to show steady growth, driven by strong demand for specialty pharmaceuticals, particularly oncology treatments [4]. - The Prescription Technology Solutions segment is projected to see revenues of $1.33 billion, a 12.3% year-over-year improvement, supported by strong demand for technology services [9]. - The Medical Surgical Solutions segment is estimated to generate $2.8 billion, reflecting a 1.5% decline year-over-year due to less demand for illness season products [11]. Strategic Initiatives - McKesson has expanded its distribution network by opening new technologically advanced centers and acquiring stakes in oncology-related ventures, which are expected to enhance its service delivery and revenue growth [17][18]. - The company is leveraging advanced technologies, particularly AI, to improve service delivery and streamline operations [20]. Market Position and Performance - McKesson's shares have gained 24.1% this year, outperforming the industry, which has declined by 2.1% [21]. - The company is recognized for its extensive distribution network, which includes over 50,000 pharmacies and nearly 900,000 healthcare providers, enhancing its appeal to pharmaceutical manufacturers [19].

McKesson, Inc. (MCK) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Today, at 10:25 AM on April 23rd, a significant trading signal occurred for McKesson, Inc. (MCK) as it demonstrated a Power Inflow at a price of $687.38. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow ...

Core Insights - McKesson's stock performance has shown resilience, with a +0.27% adjustment in the latest trading session, outperforming major indices like the S&P 500, Dow, and Nasdaq [1] - The company is set to announce its earnings on May 8, 2025, with projected EPS of $9.81, reflecting a significant 58.74% increase year-over-year, and anticipated revenue of $93.7 billion, indicating a 22.72% increase [2] Group 1: Stock Performance - McKesson's stock has increased by 4.72% over the past month, contrasting with the Medical sector's decline of 7.47% and the S&P 500's decline of 4.17% [1] Group 2: Earnings Estimates - Analysts are optimistic about McKesson's upcoming earnings, with positive revisions in estimates indicating favorable business trends [3] - The Zacks Consensus EPS estimate has decreased by 0.26% in the past month, and McKesson currently holds a Zacks Rank of 3 (Hold) [5] Group 3: Valuation Metrics - McKesson has a Forward P/E ratio of 18.94, which is higher than the industry average of 16.74, suggesting it is trading at a premium [6] - The company has a PEG ratio of 1.34, compared to the industry average of 1.73, indicating a relatively favorable valuation in terms of expected earnings growth [7] Group 4: Industry Context - The Medical - Dental Supplies industry, to which McKesson belongs, has a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [7] - Research indicates that industries in the top 50% of Zacks Rank outperform those in the bottom half by a factor of 2 to 1 [8]

Group 1 - McKesson's stock closed at $679.33, showing a +1.13% change, outperforming the S&P 500's loss of 3.46% [1] - Over the last month, McKesson's shares increased by 4.85%, while the Medical sector and S&P 500 experienced losses of 10.85% and 5.27% respectively [1] Group 2 - McKesson is expected to report earnings of $9.81 per share on May 8, 2025, reflecting a year-over-year growth of 58.74% [2] - The consensus revenue estimate for McKesson is $93.7 billion, indicating a 22.72% growth compared to the same quarter last year [2] Group 3 - Recent revisions to analyst forecasts for McKesson can indicate shifts in short-term business patterns, with positive revisions suggesting a favorable business outlook [3] - The Zacks Rank system, which incorporates estimate changes, provides actionable ratings for stocks [4] Group 4 - McKesson currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 0.26% lower over the last 30 days [5] - The Forward P/E ratio for McKesson is 17.85, which is higher than the industry average of 15.09 [6] - McKesson has a PEG ratio of 1.26, compared to the Medical - Dental Supplies industry's average PEG ratio of 1.55 [6] Group 5 - The Medical - Dental Supplies industry, which includes McKesson, has a Zacks Industry Rank of 75, placing it in the top 31% of over 250 industries [7] - Industries in the top 50% of the Zacks Rank tend to outperform those in the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - McKesson Corporation has completed the acquisition of PRISM Vision Holdings for approximately $850 million, enhancing its presence in the ophthalmology and retinal management sector, which aligns with its strategy to expand specialty healthcare services beyond oncology [1] Expansion of Clinical and Distribution Capabilities - The acquisition enhances McKesson's clinical services and distribution offerings by integrating PRISM's established network, allowing for advanced retinal and ophthalmology management solutions [4] - This integration aims to create a differentiated platform for ophthalmology, reinforcing McKesson's leadership in community-based healthcare solutions [4] Strengthening Data, Analytics, and Research - The deal supports McKesson's long-term goal of expanding its data and analytics capabilities, enabling the optimization of patient outcomes and improvement in clinical research methodologies [5] - Increased investment in innovative clinical research is also facilitated, solidifying McKesson's role in advancing specialty care [6] Deepening Biopharma Partnerships - The acquisition allows McKesson to deepen its relationships with biopharma partners in the ophthalmology space, leveraging PRISM's established reputation to enhance research, distribution, and specialty care capabilities [7] Financial Impact and Growth Projections - The acquisition is expected to be accretive to McKesson's earnings, with PRISM projected to contribute 20-30 cents to adjusted earnings per share in the first 12 months, growing to 65-75 cents per share by the end of the third year [8]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on McKesson (MCK), and highlights the potential misalignment of interests between brokerage firms and retail investors [1][4][9]. Group 1: Brokerage Recommendations for McKesson - McKesson has an average brokerage recommendation (ABR) of 1.38, indicating a consensus between Strong Buy and Buy, based on 16 brokerage firms [2]. - Out of the 16 recommendations, 13 are Strong Buy, accounting for 81.3% of all recommendations [2]. Group 2: Limitations of Brokerage Recommendations - Relying solely on brokerage recommendations may not be advisable, as studies suggest they often fail to guide investors toward stocks with the highest potential for price appreciation [4]. - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, issuing five "Strong Buy" recommendations for every "Strong Sell" [5][9]. - The interests of brokerage firms may not align with those of retail investors, leading to a lack of insight into future stock price movements [6]. Group 3: Zacks Rank as an Alternative - The Zacks Rank is presented as a more reliable indicator of a stock's near-term price performance, classifying stocks into five groups from Strong Buy to Strong Sell [7]. - Unlike the ABR, the Zacks Rank is based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [10]. - The Zacks Rank is updated more frequently than the ABR, making it a timely tool for predicting future stock prices [11]. Group 4: Current Earnings Estimates for McKesson - The Zacks Consensus Estimate for McKesson's earnings for the current year remains unchanged at $32.76, indicating steady analyst views on the company's earnings prospects [12]. - The unchanged consensus estimate has resulted in a Zacks Rank of 3 (Hold) for McKesson, suggesting caution despite the Buy-equivalent ABR [13].